OBMP Receives Approval For Phase 2 Clinical Trial Of Prostate Cancer Vaccine Technology
On January 18th, 2017, (OTCMKTS:OBMP) OncBioMune Pharmaceutical, Inc, announced the receipt of acknowledgement and authorization for the Phase 2 clinical trial of the Company's proprietary vaccine technology, ProscaVax; further positioning the Company in $7.1 billion prostate cancer treatment market. ProscaVax, the Company's leading product, uses similar techniques developed for the treatment of breast cancer patients - by means of stimulating the immune system to attack its own cancer cells. ProscaVax works as a protein therapeutic cancer vaccine, which combines prostate-specific antigen PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to stimulate the patient's immune system to selectively destroy cancerous tumors without damaging healthy cells. The clinical study is being sponsored by OncBioMune Mexico S.A. de C.V., a joint venture between the Company and its planned acquisition target, Vitel Laboratorios S.A. de C.V., and being conducted at HSH IMSS, which is considered the foremost government hospital in Mexico.
This authorization comes as a tremendous vote of confidence for OncBioMune. The Company currently trades at $0.20, much cheaper than other biopharma companies in the prostate cancer market such as (NASDAQ:SGEN) Seattle Genetics, (NASDAQ:INO) Inovio Pharmaceuticals, and (NASDAQ:NYMX) Nymox Pharmaceutical Corporation. OncBioMune has a market cap of just $7.9 million, less than other companies targeting intellectual properties for prostate cancer such as (NYSE:LLY) Eli Lilly and Co and (NYSE:PFE) Pfizer Inc.
Reported on August 8th, 2016, The latest data from the Phase 1 trial of ProscaVax further reinforced the safety and benefit of the novel cancer vaccine. Among the 16 patients enrolled in the Phase 1a trial, no serious adverse events have been reported. Additional preliminary data from the trial shows ProscaVax to provide a meaningful clinical benefit to prostate cancer patients. This data includes:
- - 15 of 20 patients in the Phase 1a portion of the trial have received at least one vaccine injection and 14 patients have received all 6 vaccines
- - None of the 15 patients who have had at least one vaccine have had a dose limiting adverse event (DLAE)
- - None of the 14 patients who have received all 6 vaccines in the Phase 1a have had a DLAE
- - 9 of the 12 patients (75%) who have received 6 vaccines have had increased immune responses to PSA as determined with a LBA (lymphocyte blastogenesis assay)
- - 9 of 11 patients (82%) at 31 weeks post first vaccine have had an increased immune response to PSA as determined with a LBA
- - Three of the 14 patients who have received all 6 vaccines have experienced disease progression (one radiological, two PSA)
OncBioMune Pharmaceuticals was founded by the two men behind the first patented autologous breast cancer vaccine, Dr. Jonathan Head and Dr. Robert Elliott. The Company is leveraging technology that has been shown in hundreds of patients to be safe. ProscaVax aims to address the 200,000 patients diagnosed with prostate cancer annually.
- OncBioMune on Facebook
- OncBioMune on Twitter
- OncBioMune on LinkedIn
- OncBioMune on SlideShare
No comments:
Post a Comment